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The CLN2 form of neuronal ceroid lipofuscinosis is a neurodegenerative disease that results from mu-
tations in the TPP1 gene. Affected children exhibit progressive declines in most neurological functions
including vision. Functional declines are accompanied by progressive brain and retinal atrophy. TPP1
encodes the soluble lysosomal enzyme tripeptidyl peptidase-1 (TPP1). Dachshunds with a TPP1 null
mutation exhibit a disorder very similar to human CLN2 disease. Periodic infusion of recombinant TPP1
protein or a single injection of a TPP1 gene therapy vector into the cerebrospinal ﬂuid of affected dogs
signiﬁcantly delays the onset and progression of neurological signs but does not slow vision loss or
retinal degeneration. Studies were conducted to determine whether intravitreal implantation of autol-
ogous bone marrow derived stem cells transduced with a TPP1 expression construct would inhibit retinal
degeneration in the canine model. A single injection of the transduced cells at an early stage in the
disease progression substantially inhibited the development of disease-related retinal function deﬁcits
and structural changes. No adverse effects of the treatment were detected. These ﬁndings indicate that
ex vivo gene therapy using autologous stem cells is an effective means of achieving sustained delivery of
therapeutic compounds to tissues such as the retina for which systemic administration would be
ineffective.
© 2016 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
The CLN2 form of neuronal ceroid lipofuscinosis (NCL) is an
inherited, autosomal recessive lysosomal storage disease charac-
terized by progressive neurological decline and vision loss. CLN2
disease results frommutations in the TPP1 gene, which encodes the
soluble lysosomal enzyme tripeptidyl peptidase-1 (TPP1) (Sleat
et al., 1997). Deﬁciencies in this enzyme result in clinical signsology, School of Medicine,
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Ltd. This is an open access article uthat include seizures, loss of motor function, ataxia, dementia,
impaired swallowing and respiration as well as progressive vision
loss culminating in blindness. Death usually occurs by early to mid-
adolescence due primarily to the secondary effects of severe
neurological impairment (Andermann et al., 1988; Caraballo et al.,
2005; Mole et al., 2011; Taratuto et al., 1995). Diseases that result
from deﬁciencies in soluble lysosomal enzymes are amenable to
treatments in which a functional version of the enzyme is admin-
istered to the affected individual and is taken up via normal cellular
lysosomal transport mechanisms into the lysosomes of the target
cells where it then performs its normal function (Sands and
Davidson, 2006). Dachshunds with a naturally occurring null mu-
tation in TPP1 have been established as model for CLN2 disease
(Awano et al., 2006; Katz et al., 2008, 2014; Sanders et al., 2011;
Whiting et al., 2013, 2015). Previous studies with the canine
model have demonstrated that periodic infusion of recombinant
TPP1 into the cerebrospinal ﬂuid (CSF) or transduction of cellsnder the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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effective in delaying the onset and progression of neurological
disease signs that result from the underlying enzyme deﬁciency
(Katz et al., 2014, 2015; Vuillemenot et al., 2011; Vuillemenot et al.,
2015; Whiting et al., 2014). However, these treatments did not
inhibit the progressive decline in electrophysiological responses of
the retina to light stimuli because the CSF, and therefore TPP1
within the CSF, does not contact any part of the retina other than
the axons of the retinal ganglion cells. Therefore, effective enzyme
replacement therapy for the retina in CLN2 disease will likely
require direct and sustained delivery of the TPP1 protein to the
retina.
The use of repeated intravitreal injections for administration of
therapeutic agents to the retina can be effective for treating
degenerative eye diseases but is far from ideal (Colucciello, 2015;
Dedania and Bakri, 2015; Gardlik and Fusekova, 2015; Modi et al.,
2015; Ramsey et al., 2014; Schwartz et al., 2014; Shikari et al.,
2014; Song and Xia, 2015). Intraocular injections are associated
with risks for injury and inﬂammation, and repeated injectionsmay
lead to formation of scar tissue at the injection sites. In addition, the
cumulative costs of such treatments are high. Direct administration
of a TPP1 gene therapy vector to the retina is a possible alternative
method of achieving long-term sustained delivery of the TPP1
protein to the retina. However, inducing high levels of TPP1 syn-
thesis and secretion by the highly specialized cells that make up the
retinawould entail the risk of disrupting normal retinal function by
upsetting the precise intracellular homeostasis and intercellular
interactions that are required to maintain normal retinal function.
An alternative approach for long-term intraocular delivery of
therapeutic agents is to implant transgenic cells into the vitreous
that would continuously produce and release therapeutic agents. In
the case of CLN2 disease, studies were undertaken to evaluate the
therapeutic efﬁcacy of an ex vivo gene therapy approach using
genetically modiﬁed autologous mesenchymal stem cells for sus-
tained delivery of TPP1 to the retina using the Dachshund model.
2. Materials and methods
2.1. Animals
A research colony of miniature long-haired Dachshunds was
established by breeding from an original pair of Dachshunds that
were heterozygous for a one nucleotide deletion (c.325delC) in
exon 4 of TPP1 (Awano et al., 2006). The mutation results in a frame
shift and a complete absence of TPP1 enzymatic activity in dogs
that are homozygous for the mutant allele. Dogs that are homo-
zygous for the mutant allele suffer from a progressive neurode-
generative disease analogous to the CLN2 form of human late-
infantile neuronal ceroid lipofuscinosis (Awano et al., 2006; Katz
et al., 2008, 2014, 2015; Vuillemenot et al., 2011). Among the
signs exhibited by the affected dogs is progressive retinal degen-
eration accompanied by loss of retinal function (Katz et al., 2008;
Whiting et al., 2013, 2015). Heterozygous dogs are phenotypically
normal. Breedings consisted of carrier to carrier crosses and female
carrier to affected male crosses. To maintain background genetic
heterogeneity, periodically carrier males were bred to unrelated
normal females from various sources outside of the colony. For the
carrier to carrier and carrier to affected crosses, dogs were bred that
had no common ancestor for at least the two previous generations.
Puppies were genotyped within several weeks of birth at the TPP1
c.325 locus using an allelic discrimination assay that distinguishes
the normal and mutant alleles (Awano et al., 2006). Dogs were
housed and bred in AALAC-accredited facilities maintained by the
University of Missouri Ofﬁce of Animal Resources. Dogs were
maintained on a 12:12 daily light cycle and were socialized daily inaddition to receiving routine husbandry care. All studies were
performed in compliance with the U.S. National Institutes of Health
Guide for the Care and Use of Laboratory Animals and were
approved by the University of Missouri Animal Care and Use
Committee.
Prior to inclusion in the study, all dogs received a complete
ophthalmic examination at 10e12 weeks of age, before the onset of
any signs of retinal or neurological impairment due to CLN2 disease
in the affected dogs. Any dogs with evidence of vision compromise
or ophthalmic conditions deemed threatening to vision were
excluded from the study. All dogs received ophthalmic examina-
tions monthly throughout the study. Examinations included
visually-mediated behavioral assessment and slit lamp bio-
microscopy (SL14; Kowa Co. Ltd., Tokyo, Japan), and indirect oph-
thalmoloscopy. Pupils were dilated with a short-acting mydriatic
(tropicamide 1%; Alcon, Fort Worth, TX), and indirect ophthal-
moscopy (12500, Welch Allyn Inc., Skaneateles Falls, NY, USA) was
performed. Fundus photographs were taken following examination
(Retcam Shuttle, Clarity Medical Systems, Pleasantown, CA) and
archived electronically. Photos were reviewed to evaluate for ab-
normalities in retinal appearance.
2.2. Bone marrow harvest and mesenchymal stem cell culture
Bone marrow aspirates were collected from each dog at
approximately 10e12 weeks of age using a modiﬁcation of proced-
ures described previously (Frimberger et al., 2006). Dogs were
sedated with intramuscular injections of dexmedetomidine hydro-
chloride and morphine followed by induction of anesthesia with
intravenous propofol administration to effect (PropoFlo 28, Abbott
Laboratories, Abbott Park, IL). Dogs were intubated with a cuffed
endotracheal tube and anesthesia maintained with isoﬂurane (1.5%
vaporizer setting; Terrell, Piramal Healthcare, Boise, ID) in oxygen
during the aspiration process. A local intramuscular injection of
lidocaine was administered just prior to aspirate collection.
Bone marrow was aseptically collected from the humerus. The
hair on the forelimb over the proximal end of the humerus was
clipped, shaved and surgically prepared. The proximal portion of
the greater tubercle was palpated and a small incision over this
structure was made using a #15 surgical blade. A 15 gauge Illinois
sternal/iliac bone marrow needle was introduced through the
incision and pushed into contact with the lateral portion of the
greater tubercle in the fossa where the lateral glenohumeral liga-
ment attaches. The needle was passed into the bone using a drilling
motion aiming the needle at an angle to pass down the medullary
cavity. When the needle had penetrated fully through the cortex,
the needle was advanced down the medullary canal for a short
distance and the stylet was removed. A 10 mL syringe containing
0.2 mL preservative-free heparin was attached to the needle, and
approximately 5 mL of marrow was withdrawn while the needle
was continuously rotated to prevent possible clot formation. The
needle was then withdrawn and the marrow was expelled into
3 mL of sterile 1X Minimum Essential Medium (MEM) Alpha
(Thermo Scientiﬁc cat. No. SH30265.02).
The bone marrow preparation was vortexed for 30 s and then
spun for 10 min at 1591  g (Unico Powerspin centrifuge, “Blood”
preset) to pellet the cells. Using sterile procedures, the supernatant
was removed and discarded and the cells were suspended in 5 mL
of fresh stem cell culture medium (SCCM), consisting of 1X MEM
alpha, 20% fetal bovine serum (Thermo Scientiﬁc cat. No.
SH30088.03/Gibco 16000-077), and 1X penicillin/streptomycin
(Thermo Scientiﬁc cat. No. SV30010). The cell suspensions were
plated onto sterile 100 mm  20 mm culture dishes and additional
SCCM was added to each dish to bring the total volume to 10 mL.
The cells were then placed in a sterile incubator at 37 C with 5%
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drawn off, the dishes were washed with sterile 1X phosphate-
buffered saline (PBS) diluted from 10X solution (Fisher Bio-
Reagents cat. No. BP399.4), and 10 mL of fresh SCCM was added to
the dishes.
Every 2e4 days the SCCM was aspirated from the cultures and
replaced with fresh SCCM. After the cells reached conﬂuence, the
medium was removed, the cells were washed with PBS, and then
incubated for 12e15min at 37 C in freshly-thawed 0.05% trypsin in
PBS. Plates were brieﬂy removed from the incubator after 6 and
12 min and subjected to gentle physical agitation in order to
facilitate cell detachment. The trypsin was then inactivated by the
addition of SCCM (volume equal to 4x the amount of trypsin used).
The cell suspension was then replated at 50% conﬂuence, and the
cells were incubated until again conﬂuent. The cells that remained
attached to the dish at this point were designated mesenchymal
stem cells (MSCs) based on accepted criteria (Fernandez Vallone
et al., 2013; Frausin et al., 2015; Kfoury and Scadden, 2015).
2.3. Transduction of mesenchymal stem cells with GFP and TPP1
expression constructs
After reaching passage 3, the cells were either transduced
directly while attached to dishes or detached from the dishes as
described in the previous section and transduced in suspension.
The concentration of cells on each dish was estimated via density
(numbers of cells per 1 mm2 were then extrapolated to available
surface area on each dish). If transduced in suspension, the cells
were pelleted after trypsinization and resuspended in SCCM prior
to treatment with the transduction vector. The resulting cell sus-
pensions were then transduced with an AAV2-CAG vector back-
bone containing a GFP-expression construct (SignaGen cat. No.
SL00816) or a TPP1-expression construct derived from human TPP1
cDNA (SignaGen cat. No. SL100801). The frozen vector stock solu-
tionwas thawed, and an aliquot was added to the cell suspension to
achieve a multiplicity of infection (MOI) of 50,000 for AAV2-CAG-
TPP1 or 10,000 for AAV2-CAG-GFP. The suspension was gently
mixed and then plated and incubated for approximately 96 h at
37 C in 5% CO2. If transduced while plated, the cells were washed
with PBS, followed by addition of SCCM containing sufﬁcient
amounts of either of the vectors to achieve the same MOIs as were
used for the cells in suspension. After 96 h the medium containing
the vectors was replaced with fresh SCCM, and the cells were
cultured in this medium until implantation.
The treated cells were evaluated for GFP expression using a Leica
DMI 6000B inverted microscope equipped for epi-ﬂuorescence and
phase contrast imaging. Adherent cells were examined with both
phase contrast and ﬂuorescence imaging modes to assess the
proportions of cells that expressed GFP. Fluorescence images were
acquired using Leica ﬁlter cube L5 ET. To assess TPP1 expression in
cells transduced with the AAV2-CAG-TPP1 vector, plates of trans-
duced and non-transduced cells from the same dog were washed
with PBS and SCCM was added. Twenty-four hours later, the
conditioned SCCM was drawn from the culture dishes and frozen
at 80 C for later determination of TPP1 enzyme activity.
2.4. TPP1 enzyme activity assay
The rate of TPP1 output per cell after transduction was quanti-
ﬁed by measuring TPP1 enzyme activity in the 24-h conditioned
medium using an assay described previously (Chang et al., 2008).
Conditioned SCCM (10 mL) was added to wells of a 96-well black
wall plate containing 80 mL sodium citrate buffer (pH 4.0). The
enzyme reaction was initiated by addition of 10 mL substrate
(250 mM Ala-Ala-Phe 7-amido-4-methylcoumarin; Sigma-Aldrichcat. no. A3401; in sodium citrate buffer, pH 4.0). Plates were then
incubated in a SpectraMax i3microplate reader (Molecular Devices,
Sunnyvale, CA) at 37 C and ﬂuorescence emission was monitored
with 360 nm excitation (9 nm bandwidth) and a 460 nm emission
ﬁlter (15 nm bandwidth). Speciﬁc activity was used to calculate the
amount of TPP1 per volume of SCCM, divided by the estimated
number of cells per plate, then used to determine TPP1 output per
unit of time per cell. Speciﬁc activity was determined by per-
forming the same assay with known amounts of puriﬁed TPP1 as
standards (R&D Systems cat. no. 2237-SE-010).
2.5. Implantation of mesenchymal stem cells into the vitreous
The TPP1 and GFP-expressing MSCs were implanted into the
vitreous of the same dog from which the cells were derived. Three
dogs received intravitreal injections of only GFP-expressing MSCs,
with one dog receiving 2e3 million cells and the other two 10e13
million cells. For the remaining dogs, approximately 2e3 million
TPP1-expressing cells were implanted in the left eye of CLN2-
affected dogs in a low-dose treatment group (n ¼ 2), while 10e13
million TPP1 cells were implanted in the left eye of affected dogs in
the high-dose treatment group (n¼ 4). GFP cells were implanted in
the right eye of all dogs in the high-dose treatment group to serve
as controls. For each dog the number of GFP cells implanted into the
right eye was equal to the number of TPP1 cells implanted into the
left eye. The right eyes of dogs in the low-dose treatment group
were untreated. Implantationwas performed 2e3weeks after bone
marrow aspiration, at approximately 14 weeks of age. Starting 1
week prior to the planned injection, cyclosporine was administered
at 25 mg BID. Cyclosporine administration continued at this dose
until the dog reached a weight of 4 kg, after which the dose was
increased to 35 mg BID. Cyclosporine administration at this dose
was continued until the dog was euthanized. On the day of injec-
tion, the cells were harvested from the culture dishes as described
previously for cell passaging, pelleted, and then suspended in SCCM
at concentrations of 9.5 (TPP1), 12.5 (TPP1), 30 (TPP1/GFP), 31.3
(TPP1/GFP), 33.3 (TPP1/GFP), 48 (TPP1/GFP) million cells per mL and
either injected immediately or held at 37 C for 60e90 min prior to
injection.
Starting approximately 1 h prior to the planned injection,
prednisolone acetate 1% ophthalmic suspension and tropicamide
1% ophthalmic solutionwere alternately administered every 10min
for a total of 3 doses of each medication. Just prior to the injection
procedure, 0.2 mg/kg dexamethasone (2 mg/mL) was administered
intravenously. The dogs were placed under general anesthesia as
described above for the bone marrow aspirations and maintained
on a ventilator. The eyes were washed with dilute betadine. The
tube containing the cell suspension was inverted gently several
times, and the suspension was then drawn into a sterile 1 mL sy-
ringe with a 1 inch 27 gauge needle. 200e400 mL of the cell sus-
pension was injected into the vitreous with the needle entry point
7 mm posterior to the limbus and needle trajectory pointed to-
wards the optic nerve, with the injection made from the top of the
eye. Immediately following the procedure, 2 mg of triamcinolone
acetonide was injected sub-Tenon's. Prednisolone acetate 1%
ophthalmic suspension was administered twice daily for one week
following the procedure, and tropicamide 1% ophthalmic solution
was administered once daily (as needed) for one week following
the procedure. After one week, 2.2 mg/kg carprofen PO BID was
administered if uveitis was observed.
2.6. In vivo imaging of implanted cells
For all dogs, in vivo imaging of the eye was performed imme-
diately following intravitreal injection of the cells and was repeated
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using a combined confocal scanning laser ophthalmoscope (SLO)
and spectral-domain optical coherence tomography (OCT) instru-
ment (Spectralis HRA/OCT, Heidelberg, Germany). The pupils were
dilated with 1% tropicamide (Alcon, Fort Worth, TX) and dogs were
placed under general anesthesia for imaging. A 55 lens was used to
obtain wide-angle SLO fundus images. Cross-sectional OCT images
of the retina were obtained in groups of parallel linear scans of
40e50 sequential B-scans each separated by 200 mm in both the
superior and inferior retina.
SLO fundus images were analyzed quantitatively with Adobe
Photoshop to determine the percentage of retinal area covered by
detachment lesions in a region of the retina superior to the optic
nerve head and were scored as follows: Grade 0 indicating no le-
sions were detected; Grade 1 indicating that less than 15% of the
retina was affected by lesions; Grade 2 indicating that greater than
15% but less than 30% of the retina was affected by lesions; and
Grade 3 indicating that 30% or greater of the retina was affected by
lesions (Whiting et al., 2015).
2.7. Electroretinography
Bilateral electroretinogram (ERG) evaluations were performed
for all treated TPP1/ dogs on an approximately monthly basis
beginning 1 month post-MSC implantation as described previously
(10). Dogs were prepared for ERG recording in ambient room light.
Prior to recording, both pupils were dilated with 1% tropicamide,
and dogs were deeply sedated with intramuscular administration
of dexmedetomidine (20e30 mg/kg) and ketamine (4 mg/kg). The
use of ketamine was discontinued in dogs 8 months of age and
older due to the increased risk of seizures in CLN2-affected dogs.
ERGs were elicited bilaterally and recorded simultaneously with a
commercial instrument (HMsERG model 2000; RetVet Corp.,
Columbia, MO). Each ERG session consisted of scotopic and phot-
opic recordings in accordance with the Dog Diagnostic Protocol,
recommended by the European College of Veterinary Ophthal-
mology, primarily for evaluation of rod and cone function (Ekesten
et al., 2013). During a 20 min period of dark adaptation, scotopic
low-intensity rod responses were elicited at a stimulus intensity of
0.01 cd s/m2 with 4 min of dark adaptation between recordings.
Following this, scotopic responses were elicited using ﬂashes of
3 cd s/m2 and 10 cd s/m2 to evaluate mixed rod and cone function.
The eyes were then exposed to diffuse white light at a luminance of
30 cd/m2 for 10 min, immediately after which responses to single
3 cd s/m2 ﬂash stimuli were recorded. This was immediately fol-
lowed by evaluation of responses to 30-Hz photopic ﬂicker stimuli
at the same light intensity. ERG waveforms in all recordings were
evaluated, and the amplitudes and implicit times for the a- and b-
waves were measured as previously described (Whiting et al.,
2013).
2.8. Post-enucleation characterization of implanted cells and
retinas
The dogs that received the GFP-expressing cells alone were
euthanized at 52e70 days post-injection, and the remaining dogs
were euthanized when they reached disease end-stage at approx-
imately 11 months of age. The dogs were sedated with dexmede-
tomidine followed by euthanasia with Fatal Plus (sodium
pentobarbital). The eyes were enucleated immediately and for the
dogs that received implants of GFP-expressing cells alone, the eyes
were placed in a ﬁxative consisting of 3.5% paraformaldehyde,
0.075% glutaraldehyde, 0.12 M sodium cacodylate, 0.5 mM CaCl2,
pH 7.4. For the remaining dogs, the eyes were ﬁxed in 2.5%
glutaraldehyde, 0.1 M sodium cacodylate pH 7.4. The cornea, iris,and lens were removed from each eye and the remainder of the eye
was processed for further evaluations. For those eyes ﬁxed in the
2.5% glutaraldehyde, the vitreous body was removed at the time of
ﬁxation, whereas for the remaining eyes the vitreous was left in the
eyecups until subsequent evaluation and dissection. The remainder
of each eye was incubated in the ﬁxative with gentle agitation at
room temperature. For dogs that received the GFP-expressing cells
only, the ﬁxative was replaced with a solution of 0.17 M sodium
cacodylate, pH 7.4 after approximately 24 h. Eyes to be used for
histopathological examination were kept in the 2.5% glutaralde-
hyde ﬁxative for at least 24 h and left in this ﬁxative until being
processed for microscopic examination.
To localize the implanted cells in eyes that were injected with
the GFP-expressing MSCs, the eyecups with the vitreous intact
were examined with a Leica MZFLIII microscope with epi-
illumination from a xenon lamp and using a Leica GFP ﬁlter set.
Clusters of autoﬂuorescent GFP cells large enough to visualize in
the vitreous were dissected from the eyecups along with the sur-
rounding vitreous and transferred to vials containing the cacody-
late buffer and photographed using the MZFLIII microscope or a
Zeiss Axiophot microscope using epi-illumination from a xenon
lamp and a Chroma NC322124 ﬁlter set optimized for visualization
of GFP ﬂuorescence (Chroma Technology, Rockingham, VT). The
autoﬂuorescent cell clusters were then transferred to the 2.5%
glutaraldehyde ﬁxative and after at least 24 h were processed and
embedded in epoxy resin (Katz et al., 2008).
To determine whether any of the implanted GFP-expressing
cells had migrated into the retinas, eyecups ﬁxed for ﬂuorescence
microscopy were dissected and processed for cryostat sectioning.
Segments of the eyecups were incubated sequentially in 10% su-
crose, 20% sucrose, 1:1 20% sucrose:TissueTek (Sakura Finetek,
Torrance, CA), and pure TissueTek. The sucrose solutions contained
0.1 M sodium cacodylate. The samples were then incubated in
embedding molds ﬁlled with TissueTek for 40 min and then frozen
by placing the embedding molds directly on blocks of dry ice.
Sections of the frozen samples were cut with a Microm H525
(Microm International, Waldorf, Germany) cryostat at a thickness of
8 mm. The sections were mounted on SuperFrost slides (Fisher
Scientiﬁc) in 0.17 M sodium cacodylate buffer and examined with a
Zeiss Axiophot microscope using epi-illumination from a xenon
lamp and the Chroma NC322124 ﬁlter set.
To evaluate the effect of the MSC implantations on retinal
morphology, segments of the glutaraldehyde-ﬁxed retinas were
examined using conventional histological techniques (Katz et al.,
2005). The 2.5% glutaraldehyde-ﬁxed eyecups were dissected to
obtain regions of the retina adjacent to the optic nerve heads. The
retina and cell cluster samples were then washed in cacodylate
buffer, post-ﬁxed with 1% osmium tetroxide, and embedded in
epoxy resin. Sections of the embedded samples were cut and
stained with toluidine blue. The sections were examined with
transmitted light microscopy.2.9. Statistical analysis
All statistical tests were performed using SigmaPlot (Systat
Software Inc., San Jose, CA). Data were subjected to the Shapiro-
Wilk test to conﬁrm normal distribution. Repeated measures 2-
way ANOVA was used to compare ERG data from CLN2-affected
eyes treated with TPP1-producing MSCs to those from untreated,
CLN2-affected dogs to determine if the treatment was able to
prevent deﬁcits in ERG b-wave amplitude related to CLN2 disease
progression. Follow-up pairwise comparisons were performed
with the Holm-Sidak correction (a ¼ 0.05) to control family-wise
error rate.
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3.1. Transgene expression in bone marrow-derived MSCs
After incubation with the AAV2 vectors the cultured cells
exhibited rapid and robust expression of the transgenes. Based on
GFP autoﬂuorescence or TPP1 activity measurements, peak
expression was achieved within approximately 5 days after expo-
sure of the cells to the vector. Based on GFP autoﬂuorescence, close
to 100% of the cultured cells expressed the transgene (Tracy et al.,
2015). The intensity of the autoﬂuorescence did not decline over
a period of 4 weeks if the cGFP-transduced cells were held at
conﬂuence, nor did the number of cells expressing visible GFP
autoﬂuorescence decline when the cells were passaged up to 5
times after incubation with the AAV2-CAG-GFP vector. The rate of
release of TPP1 from the cells into the culture medium just prior to
harvest for implantationwas an average of 3e5 pg per cell per 24 hFig. 1. Images of GFP-expressing MSCs in the vitreous of two TPP1/ dogs. Images (AeD) w
injected cell suspensions can be seen in black in the SLO images (A) and (C) and in white in au
was due to GFP expression since no such autoﬂuorescence was observed in injected cells tran
vitreous of aTPP1/ dog 9 weeks after injection. A cluster of GFP-expressing cells can be se
(E). In a cross-section OCT image of the same area (F), an area of the retina below the intravi
between arrows in F). The horizontal lines in (E) indicate planes in which OCT images of th
image shown in (F).in all cases and the release rate remained stable over the 3 days
prior to harvest of the cells for implantation into the vitreous.
3.2. Behavior of the MSCs after implantation into the vitreous
The MSCs could be visualized in the vitreous immediately after
implantation using the Spectralis instrument in either SLO and, for
the GFP-expressing cells, in ﬂuorescence mode (Fig. 1). The sizes of
these cell clusters that could be visualized in vivo declined over
time, and in the majority of cases the clusters eventually became
too small to detect with the described in vivo imaging techniques. In
some eyes residual clusters of cells could still be seen for at least 9
weeks post-injection (Fig. 1). In order to assess the distribution of
the injected GFP-expressing cells in cases in which in vivo visuali-
zation was still possible, such eyes were enucleated between 4 and
9 weeks post-injection and the vitreous and retina were examined
for the presence and distribution of these cells. In some eyes aere taken in vivowith the Spectralis™ equipment immediately following injection. The
to-ﬂuorescence mode on the Spectralis (B) and (D). The autoﬂuorescence in (B) and (D)
sduced with the AAV2-CAG-TPP1 vector. Images (E and F): GFP-expressing MSCs in the
en in the vitreous in an image obtained with the Spectralis™ in autoﬂuorescence mode
treal cell cluster is not visible due to the shadow cast by the overlying cell cluster (area
e retina were obtained. The yellow line indicates the location of the plane of the OCT
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50 mm3 could be observed suspended in the vitreous with the
ﬂuorescence stereoscope (Fig. 2A), as well as much smaller clusters
of autoﬂuorescent cells scattered throughout the vitreous (Fig. 2B).
The largest cell clusters were centrally located in the vitreous
whereas the smaller clusters were relatively uniformly dispersed
throughout the vitreous. No GFP expressing cells were observed
adhered to either the posterior lens capsule or the vitreal surface of
the retina. No integration of the implanted cells into the retina was
observed in either whole-mount preparations or in crysostatFig. 2. Images of GFP-expressing MSCs at a long post-implantation time. One dog was
euthanized at 52 days post-injection and after removal of the cornea, iris and lens, the
vitreous of the eye injected with GFP-expressing MSCs was examined for GFP ﬂuo-
rescence using a Leica MZFLIII stereoscope. A large aggregate of GFP-expressing cells
(A) as well as numerous small aggregates of these cells (B) were observed scattered
throughout the vitreous. The large aggregate was dissected from the vitreous, post-
ﬁxed with osmium tetroxide and embedded in epoxy resin. Toluidine blue stained
sections of the aggregate revealed that it consisted of cells with ﬁbroblast-like mor-
phologies distributed throughout an extracellular matrix (C).sections of the eye. We were able to dissect the largest clusters of
GFP-expressing cells from the vitreous and after ﬁxation and
embedding in plastic, observe their histological appearance.
The cells in these clusters exhibited ﬁbroblast-like morphologies
and were embedded in a lightly staining extracelluar matrix
(Fig. 2C).
3.3. Preservation of retinal structure and function
The control eyes of the CLN2-affected dogs developed localized
retinal detachments that increased in number and size as the
disease progressed, typical of this disease (Fig. 3) (Whiting et al.,
2015). There was a signiﬁcant reduction in prevalence of the
disease-related localized retinal detachments in the eye treated
with TPP1-expressing MSCs compared to the control eye in each of
the dogs in the high dose group (Fig. 3). Age of onset of CLN2-
related retinal detachment lesions varies greatly among un-
treated dogs, but once the lesions appear, the number and size of
the lesions progress at approximately the same rate in both eyes
(Whiting et al., 2015). Of the three dogs in the high dose group
that developed progressive multifocal retinal detachments in the
control eye, lesions were entirely prevented in the TPP1-treated
eye of 2 dogs (Fig. 3, dogs A and C). The third dog exhibited se-
vere lesions in the control eye (occupying 25% of the superior
retina by 10 months of age), but only a small number of lesions in
the treated eye at the same age (occupying 5% of the area of the
superior retina) (Fig. 3, dog B). One of the dogs in the high dose
treatment group did not develop detachment lesions in either eye
during the study.
Intravitreal injection of TPP1-producing MSCs signiﬁcantly
inhibited the disease-related decline in ERG amplitudes relative to
the decline in amplitudes observed in the contralateral control
eyes (Figs. 4 and 5). The observed amplitude declines with
advancing age in the control eyes were typical of those reported
previously in Dachshunds with untreated CLN2 disease (Whiting
et al., 2014). Dogs in the high dose treatment group showed a
greater preservation of the ERG than those in the low dose
treatment group (data not shown). Untreated, CLN2-affected dogs
have signiﬁcantly reduced ERG b-wave amplitudes by 5 months of
age under a scotopic high intensity stimulus condition (Whiting
et al., 2014). Conversely, in dogs receiving the high dose of
TPP1-producing MSCs, the treated eye exhibited a full preserva-
tion of the ERG through 7 months of age. There was no signiﬁcant
difference between the b-wave amplitude of treated eyes and
normal, age-matched eyes until 8 months of age representing a 3
month delay in the onset of ERG deﬁcits in the TPP1-treated eyes
(Fig. 5A). Between 8 and 10 months of age, while there was a
signiﬁcant reduction from normal of b-wave amplitudes in the
treated eyes, amplitudes were still signiﬁcantly improved over
those of untreated dogs at these ages (p < 0.001) (Fig. 5A). It is
worth noting that deﬁcits in a-wave amplitude of both untreated
and treated CLN2-affected eyes ﬁrst appear at 8 months, the same
age at which b-wave deﬁcits are ﬁrst apparent in TPP1-treated
eyes (Fig. 5B). In addition, despite deﬁcits in absolute b-wave
and a-wave amplitudes, b-wave to a-wave amplitude ratios are
fully preserved in treated eyes between 8 and 10 months of age
(Fig. 5C).
Lesion prevalence varied amongst the eyes of affected dogs that
received injections of GFP-MSCs as measured by the percent of the
retinal area occupied by these lesions. When ERG a-wave data were
evaluated separately in dogs inwhich the lesions were mild (15% or
less of the retinal area occupied by the lesions) or severe (greater
than 15% of the retina occupied by lesions), the deﬁcits in a-wave
amplitudes were more pronounced in the eyes with the more se-
vere lesions (Fig. 5D).
Fig. 3. Intravitreal implantation of TPP1-producing MSCs preserves retinal structure in CLN2-affected dogs from the high dose treatment group. Retinal detachment lesions are fully
prevented in the TPP1-treated eye of dog A through 10 months of age (A), while they progress signiﬁcantly between 6 and 10 months of age in the control eye covering 36% of the
superior retina by end-stage neurologic disease (B). Lesions observed in the control images of panel A are localized retinal detachments which disrupt the outer retinal layers (C).
Colored arrows in panel A correlate to the locations indicated by the same colored arrows in panel C. By end-stage neurologic disease at 10 months of age, implantation of the TPP1-
producing MSCs had either completely prevented or substantially reduced the number and size of the localized retinal detachments in 3 of the high-dose dogs (D). The fourth dog in
the high-dose treatment group did not develop detachment lesions in either eye during the study period; age of lesion onset varies greatly between dogs.
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When the dogs reached end-stage disease and were euthanized,
each retina was examined for histopathological abnormalities
associated with the CLN2 disease and for possible adverse effects of
the implanted cells. The eyes treated with the TPP1 expressing cells
had normal appearing morphology with no pathological changesapparent in any of the retinal layers (Fig. 6A). By contrast, the eyes
that received the implants of GFP-expressing cells had localized
areas where the retina had separated from the underlying retinal
pigment epithelium (Fig. 6B) that appeared to correspond to the
areas of localized retinal detachment observed in vivo with OCT
imaging. In these areas, which varied greatly in size, all of the
retinal layers appeared thinner than the corresponding layers of the
Fig. 4. Intravitreal implantation of TPP1-producing MSCs preserves retinal function. Rod (A), mixed rod and cone (B), cone (C), and 30 Hz ﬂicker (D) ERG responses are all preserved
through 10 months of age in the TPP1-treated eye of a CLN2-affected dog from the high dose treatment group. Conversely, each response gradually deteriorates in the control eye
over time.
Fig. 5. Preservation of inner retinal function in dogs receiving intravitreal TPP1-producing MSCs. (A) Remarkably, eyes receiving the high dose treatment showed a 3 month delay in
the onset of ERG deﬁcits and had a signiﬁcant preservation of the mixed rod-cone ERG b-wave amplitudes between 5 and 10 months of age when compared to amplitudes from the
control eyes (*p  0.001, zp0.01). (B) The a-wave amplitudes in the eyes receiving high dose treatment began to decline at approximately the same age at which b-wave deﬁcits
ﬁrst presented in the treated eyes. This timing is also consistent with the progression of a-wave deﬁcits observed in untreated CLN2-affected dogs. (C) The ratio of b-wave to a-wave
amplitudes declined dramatically in the control eyes as the disease progressed but was well preserved through 10 months of age in eyes receiving high-dose treatment. Amplitude
ratios of TPP1-treated dogs are signiﬁcantly greater than those of untreated, CLN2-affected dogs (*p  0.001, zp0.01) and not statistically different from those of normal dogs. (D)
Deﬁcits in a-wave amplitude are more severe in control eyes that developed severe retinal detachment lesions than in those which developed mild or no lesions.
C.J. Tracy et al. / Experimental Eye Research 152 (2016) 77e8784adjacent retina. There was an overall thinning of the control retinas
relative to those of the eyes treated with the TPP1-expressing cells,
although none of the layers were completely lost. Thephotoreceptor inner and outer segments of the control eyes were
sparse and much more disorganized than the corresponding
structures from the treated eyes. There was no evidence that any of
Fig. 6. Retinal morphology of treated and control eyes at disease end-stage. Light micrographs of the retinas from a TPP1/ dog that received the high dose of TPP1-expressing
cells in one eye (A) and an equivalent number of GFP-expressing cells in the other eye (B). The dog was euthanized at approximately 10.5 months of age. The asterisk in (B) indicates
one of the localized retinal detachment lesions visible in vivo in OCT images. The overall retinal thickness was substantially lower in the control eye than in the eye that received the
TPP1-expressing MSCs. Bar in (A) represents the magniﬁcation of both micrographs. Both micrographs were from regions of the retina along the eye equator within 5 mm of the
optic nerve head.
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received injections of GFP-expressing MSCs, no cells exhibiting GFP
autoﬂuorescence were observed in cryostat sections of the retinas
when examined with ﬂuorescence microscopy. Likewise, no
abnormal appearing cells were observed invading the retina in
sections of retinas from eyes that were injectedwith either the GFP-
or TPP1-expressing MSCs (Fig. 6).4. Discussion
CLN2 disease is one of a number of lysosomal storage diseases
that result from a lack of or insufﬁciency in speciﬁc soluble en-
zymes that normally perform their enzymatic activities within the
lumen of the lysosome (Mindell, 2012; Winchester, 2005; Wong
et al., 2010). These enzymes, including TPP1, are glycosylated
with mannose-6-phosphate which targets them to the lysosome
via intracellular protein sorting mechanisms that include endo-
somal transport (Brooks, 2009; Gary-Bobo et al., 2007; Hasilik et al.,
2009; Kornfeld, 1987; Nadimpalli and Amancha, 2010). Enzymes
within this class are targeted not only to the lysosomes, but also to
the cell surface where they are released into the extracellular space
after fusion of endosomal vesicles with the plasma membrane.
Most cells have cell-surface mannose-6-phosphate receptors to
which these enzymes can bind. Once bound to receptors, the pro-
teins can be taken up by the cells via invaginations of the plasma
membrane that form clathrin-coated vesicles that become part of
the intracellular endosomal system by which these proteins can be
delivered to the lysosomes. Via this mechanism, proteins with
mannose-6-phophate tags can be delivered to lysosomes by sup-
plying them to the extracellular space. This mechanism of deliv-
ering enzymes to lysosomes forms the basis of enzyme
replacement therapies that are currently being used to treat a
number of lysosomal storage diseases (Clarke, 2008; Lyseng-
Williamson, 2014; Morris, 2012; Naz et al., 2013; Schoser et al.,
2008; Thomas et al., 2014).In theory CLN2 disease should be amenable to TPP1 enzyme
replacement therapy. A challenge in using this approach for treat-
ing CLN2 disease is that the symptoms in this disorder are primarily
neurological, so in order to be therapeutically effective, TPP1
replacement enzyme must reach the central nervous system (CNS).
Because the blood brain barrier prevents large molecules, such as
TPP1, from entering the CNS from the bloodstream, systemic
administration of this protein would not be expected to ameliorate
the neurological symptoms. To overcome this barrier, in a previous
study TPP1-null Dachshunds were treated with periodic infusions
of recombinant TPP1 into the cerebrospinal ﬂuid. This signiﬁcantly
delayed the onset and slowed the progression of most of the
neurological disease symptoms and increased survival times (Katz
et al., 2014). These preclinical studies in the Dachshund model led
to human clinical trials of this approach for treating children with
CLN2 disease. The initial trial has been successfully completed
(ClinicalTrials.gov Identiﬁer: NCT01907087) and this treatment is
now available to children suffering from this disorder
(NCT02485899 and NCT02678689). An alternative approach to
delivery of TPP1 to the CNS has also been shown to be effective in
ameliorating the neurological signs of CLN2 disease in the Dachs-
hund model. An AAV2-TPP1 gene therapy vector was injected into
the cerebrospinal ﬂuid (CSF) of affected dogs at an early age. This
resulted in transduction of the ependymal cells lining the brain
ventricular system and sustained elevated levels of TPP1 protein in
the CSF (Katz et al., 2015). The therapeutic efﬁcacy of this treatment
was similar to that of the enzyme replacement approach to therapy.
One of the clinical signs of CLN2 disease in both children and in
the Dachshund model is progressive vision loss culminating in
blindness, due largely to progressive retinal degeneration. Unfor-
tunately, delivery of TPP1 to the CSF by either enzyme replacement
therapy or gene therapy did not ameliorate the retinal degenerative
changes, most likely due to the fact that the CSF does not come in
contact with the retina (Whiting et al., 2014, 2016). Therefore, in
order to prevent the blindness that is characteristic of CLN2 disease,
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Possible approaches include adapting the enzyme replacement and
gene therapy methods that were used to treat the CNS for treating
the retina. However, as stated in the introduction, both of these
approaches have signiﬁcant drawbacks. We therefore tested
intravitreal implantation of autologous MSCs transduced with a
TPP1 expression construct as a means of inhibiting retinal degen-
eration in the canine model of CLN2. As our data indicate, this
approach was very effective in inhibiting the retinal degenerative
changes that accompany this disease. In one of the dogs a single
high dose injection of TPP1-expressing MSCs resulted in almost
complete prevention of any disease-related retinal degenerative
changes over the lifespan of the dog, whereas no therapeutic
beneﬁt was observed in the contralateral eye injected with the
same number of MSCs transduced to express GFP instead of TPP1.
Although the therapeutic effects in the other 3 dogs that received
the high dose of TPP1-expressing MSCs were substantial, complete
prevention of disease-related changes was not observed in these 3
dogs.
The basis for this variability is not apparent, but based on both
this study and our previous work on TPP1 enzyme replacement
therapy (Katz et al., 2014) the efﬁcacy of the treatment is dose-
dependent. In the CNS TPP1 enzyme replacement studies we con-
ducted previously, 3 different doses were tested, and over the dose
range tested, therapeutic efﬁcacy increased with increasing dose
(Katz et al., 2014). All 3 doses were well tolerated, but even at the
highest dose complete prevention of disease symptoms was not
achieved. With the MSC delivery method, in cases where a single
injection of TPP1-expressing MSCs is found not to be sufﬁcient to
completely preserve retinal structure and function, it would likely
be possible to compensate by giving a subsequent additional in-
jection. Since TPP1 production by the transduced MSCs can be
measured prior to injection, it should be possible to achieve rela-
tively precise dose control. Prior to conducting human clinical trials
of this treatment approach, we plan to perform dose optimization
studies.
The fact that the disease-related declines in b-wave amplitudes
exceed the declines in a-wave amplitudes in the control and un-
treated eyes (Fig. 6) indicates that the disease affects inner retinal
function directly. In the eyes treated with TPP1-expressing MSCs,
the b:a wave amplitude ratios were maintained at normal levels
throughout the course of the disease (Fig. 6C). This ﬁnding indicates
that the treatment was effective in preserving the functional
integrity of the inner retinal neurons.
The presence of severe retinal detachment lesions observed in
the control eyes of 2 dogs resulted in greater deﬁcits in a-wave
amplitudes than we have previously observed in untreated, CLN2-
affected eyes that developed mild or no lesions. This is consistent
with previous data which illustrated that lesions covering 15% or
greater of the superior retina resulted in an apparent reduction in
the a-wave relative to data collected from CLN2-affected eyes that
did not develop severe lesions (Whiting et al., 2015). While these
previous results were not statistically signiﬁcant due to the small
number of dogs in which severe lesions had been observed, the
additional data from the current study appear to support this
observation. Visual pigment regeneration in rod photoreceptors
requires cycling of retinoids between the photoreceptor outer
segments and the underlying retinal pigment epithelium, which
are normally in close apposition to one another. When the retina is
detached, this cycling is impaired preventing visual pigment for-
mation that entails binding of 11-cis retinaldehdye to the rod outer
segment opsin protein. In the CLN2-affected dogs, the correlation
between severity of retinal detachment lesion and declines in ERG
a-wave amplitudes suggests that in areas where the retina is de-
tached from the RPE, the retinoid cycling between the RPE and rodouter segments is compromised. Thus the efﬁcacy of the TPP1-MSC
treatment in preserving the ERG may be attributed in part to the
prevention of retinal detachment lesions.
The efﬁcacy of this treatment suggests that genetically modiﬁed
autologous MSCs will likely be effective as vehicles for long-term
sustained targeted delivery of many other therapeutic com-
pounds in treating not only lysosomal storage diseases, but also a
variety of other disorders. For example, the common retinal dis-
order, age-related macular degeneration, is currently treated by
periodic intravitreal injections of antiangiogenic monoclonal anti-
bodies (Solomon et al., 2016). It may be possible to achieve the
same or better therapeutic beneﬁt by a single intravitreal injection
of autologous MSCs programmed to produce and secrete this
antibody. This is one of many possible applications for the ex-vivo
approach to gene therapy to provide long-term therapeutic efﬁcacy
with a single injection. The use of genetically engineered autolo-
gous MSCs as vehicles for sustained delivery of therapeutic com-
pounds is not restricted to the retina. A major hurdle in developing
therapeutics targeting the central nervous system is the inability of
many therapeutic agents, including proteins, the cross the blood
brain barrier when administered systemically. Preliminary studies
under way in our laboratory indicate that implanting TPP1
expressing autologous MSCs into the cerebrospinal ﬂuid of dogs
with CLN2 disease can inhibit the progression of neurological dis-
ease signs. Thus, this approach holds promise for treating many
disorders of the central nervous system.
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